In a significant stride toward understanding the biological underpinnings of Alzheimer’s disease, researchers at Mount Sinai have uncovered critical new evidence regarding how APOE4—the most potent genetic risk factor for the condition—triggers progressive brain damage. Two landmark studies, published concurrently in the journals Cell and Cell Stem Cell, provide a transformative look at how this gene destabilizes brain blood vessels and disrupts the brain’s ability to clear toxic proteins. Perhaps most promisingly, the research indicates that these destructive processes may be reversible, offering a potential roadmap for future therapeutic interventions.
The studies also introduce a sophisticated human brain tissue platform known as "miBrains." Developed by the team at the Icahn School of Medicine at Mount Sinai, these three-dimensional models derived from stem cells provide a new, highly accurate laboratory environment to study neurodegeneration, promising to accelerate the discovery and testing of treatments for Alzheimer’s, Parkinson’s, and other related disorders.
The Vascular Connection: Rethinking Alzheimer’s Progression
Alzheimer’s disease is a devastating condition that slowly erodes memory, cognitive function, and behavioral stability, currently affecting more than 7 million older adults in the United States alone. For decades, the scientific community has observed that the brain’s vascular system—the intricate network of blood vessels that supply oxygen and nutrients—deteriorates as Alzheimer’s progresses. This phenomenon is particularly pronounced in individuals carrying the APOE4 gene variant.
Historically, however, the medical community has viewed vascular damage as a secondary, late-stage consequence of the disease—a passive byproduct of the underlying neurodegeneration. Because of this perception, the health of the brain’s circulatory system was rarely considered a primary driver of the disease that could be targeted for treatment. The new findings from the Mount Sinai team challenge this long-standing assumption, positioning vascular degradation as an active, early-stage biological process that is directly influenced by APOE4.
In the study published in Cell on September 24, researchers utilized existing datasets to construct a single-cell transcriptomic atlas of the human brain’s vascular system. This high-resolution map allowed the team to track gene activity across the diverse cell types that maintain the vascular architecture. Their analysis revealed a critical mechanism: APOE4 forces a functional shift in pericytes, the specialized cells responsible for stabilizing small blood vessels and maintaining the integrity of the blood-brain barrier.
In the presence of APOE4, these pericytes undergo a pathological transformation, morphing into myofibroblast-like cells. Instead of protecting the vasculature, these transformed cells begin producing scar tissue, leading to vascular fibrosis. This fibrosis not only restricts essential blood flow but also facilitates the accumulation of amyloid-beta proteins around the blood vessels. This, in turn, creates a toxic environment that fosters further neurodegeneration.
Crucially, the team discovered that this cycle of destruction is not necessarily permanent. By targeting the TGF-β signaling pathway—a key regulator of cell communication and tissue remodeling—researchers were able to restore normal pericyte function, effectively reversing the fibrosis and reducing amyloid buildup. When the team tested this in aged APOE4 mice, the vascular damage was successfully mitigated, proving that the vascular degeneration associated with this genetic risk factor is potentially treatable.
"Damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible," said Joel W. Blanchard, PhD, Associate Professor of Neuroscience, and Stem Cell Biology and Regenerative Medicine at the Icahn School of Medicine at Mount Sinai, and the corresponding author of the study. "These findings reveal new therapeutic targets for preserving vascular function and limiting amyloid accumulation."
Braxton R. Schuldt, an MD/PhD candidate in Neuroscience and the study’s first author, emphasized the clinical implications of these findings. "We show that APOE4 converts blood-vessel support cells into scar-producing cells, causing amyloid or abnormal protein buildup to accumulate around the brain’s vessels. Through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain’s circulation in people at high genetic risk for Alzheimer’s disease."
Human miBrains: A New Frontier in Disease Modeling
A central pillar of this research was the use of miBrains, a revolutionary 3D human brain tissue model. By utilizing induced pluripotent stem cells, the Mount Sinai team has successfully engineered tissue that replicates the complex, multi-cellular architecture of the human brain, including the intricate web of blood vessels.
The researchers combined data from these models with preclinical findings, postmortem human tissue analysis, and extensive transcriptomic data. This multi-layered approach allowed the team to observe the disease process in real-time, effectively capturing the molecular events that occur long before the devastating vascular abnormalities are visible in postmortem brains. By recreating these early stages, the scientists were able to isolate the mechanisms behind the disease and establish a high-throughput system for testing potential pharmacological interventions.
APOE4 and the Disruption of Cellular Waste Disposal
In the companion study published in Cell Stem Cell, the team turned their attention to another major consequence of APOE4: its role in the accumulation of misfolded, toxic proteins within the brain. The buildup of these proteins—such as amyloid in Alzheimer’s and alpha-synuclein in Parkinson’s and Lewy body dementia—is a hallmark of neurodegeneration. However, studying the formation of these deposits in a living human brain has historically been nearly impossible.
The miBrain system allowed the researchers to observe how these proteins accumulate in a controlled, complex environment. They found that APOE4 causes a significant buildup of cholesterol within astrocytes—the star-shaped glial cells that provide metabolic support and maintain homeostasis in the brain. This excess cholesterol interferes with the astrocytes’ lysosomal waste-disposal systems.
Normally, the lysosome acts as the cell’s "recycling center," breaking down proteins and cellular waste. When APOE4 disrupts this process, the astrocytes lose their ability to clear alpha-synuclein. Consequently, the protein accumulates and spreads to nearby neurons, forming the toxic deposits that drive the progression of Parkinson’s and other dementias. This discovery suggests that focusing on cholesterol metabolism and lysosomal function could provide entirely new avenues for therapeutic intervention in neurodegenerative disease.
Toward Personalized Medicine and Future Therapies
The miBrain technology offers a distinct advantage in the quest for personalized medicine: the ability to cryopreserve the tissue for long-term use. This scalability is a game-changer for drug discovery, as it allows researchers to reproduce results across multiple experiments with high consistency.
"A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved," explained Louise Mesentier-Louro, PhD, Assistant Professor of Neuroscience and Stem Cell Biology and Regenerative Medicine at Mount Sinai, and first author of the Cell Stem Cell study. "This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation."
Looking ahead, the researchers are working on creating miBrains derived from individual patient samples. This evolution of the technology will allow scientists to investigate how neurodegenerative diseases manifest differently across the population and, eventually, how individual patients might respond to specific drug therapies.
"At Mount Sinai, we are creating and cryopreserving miBrains from patients," Dr. Blanchard added. "This will enable personalized studies into how neurodegenerative disease develops and how individuals may respond to therapies. By enabling potential therapies to be tested earlier and more efficiently, the miBrain platform could help bridge the gap between laboratory discoveries and treatments for a broad range of disorders."
These dual studies represent a significant leap forward in understanding the multifaceted ways APOE4 degrades brain health. By identifying specific, potentially reversible pathways—from vascular scarring to impaired cellular waste removal—the research provides a clearer, more actionable framework for developing the next generation of Alzheimer’s and Parkinson’s treatments.
The research was supported by a variety of organizations, including the National Aeronautics and Space Administration (NASA), the National Institute on Aging (NIA), the National Institute of Neurological Disorders and Stroke (NINDS), the Michael J. Fox Foundation for Parkinson’s Research through Aligning Science Across Parkinson’s (ASAP), the CureAlz Fund, and The SWT Foundation.
